Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapy.

Frontiers in immunology - 1 Jan 2024

Gronauer Raphael, Madersbacher Leonie, Monfort-Lanzas Pablo, Floriani Gabriel, Sprung Susanne, Zeimet Alain Gustave, Marth Christian, Fiegl Heidelinde, Hackl Hubert

Abstract excerpt

Background: The efficacy of immunotherapies in high-grade serous ovarian cancer (HGSOC) is limited, but clinical trials investigating the potential of combination immunotherapy including poly-ADP-ribose polymerase inhibitors (PARPis) are ongoing. Homologous recombination repair deficiency or BRCAness and the composition of the tumor microenvironment appear to play a critical role in determining the therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to Cystadenocarcinoma, Serous

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Neoplasm Grading

Share to Ovarian Neoplasms

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Single-Cell Analysis

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 39669575
DOI: 10.3389/fimmu.2024.1489235
PMCID: PMC11634877

Genes

BRCA1
C1QA
LILRB4
TREM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapy.PMID 39669575Read ↗

Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapySemantic proximity Read ↗

Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous CarcinomaSemantic proximity Read ↗

Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis.Semantic proximity Read ↗

Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune systemSemantic proximity Read ↗

Characterizing tumor biology and immune microenvironment in high-grade serous ovarian cancer via single-cell RNA sequencing: insights for targeted and personalized immunotherapy strategiesSemantic proximity Read ↗

High-Grade Serous Ovarian Carcinoma in the Genomics Era: Current Applications, Challenges and Future Directions.Semantic proximity Read ↗

The mutational landscape defines the proteome and spatial organization of tumor, stroma and immune cells in ovarian cancerSemantic proximity Read ↗

Genomic and TCR profiling data reveal the distinct molecular traits in epithelial ovarian cancer histotypes.Semantic proximity Read ↗

Identification of three subtypes of ovarian cancer and construction of prognostic models based on immune-related genes.Semantic proximity Read ↗

Classification of ovarian cancer associated with BRCA1 mutations, immune checkpoints, and tumor microenvironment based on immunogenomic profilingSemantic proximity Read ↗

Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient stratificationSemantic proximity Read ↗

Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.